Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCENTAGE-B

67.250
+2.7504.26%
Volume:2.21M
Turnover:147.15M
Market Cap:25.08B
PE:-45.77
High:68.000
Open:64.750
Low:64.400
Close:64.500
52wk High:95.350
52wk Low:31.350
Shares:373.00M
HK Float Shares:373.00M
Volume Ratio:1.03
T/O Rate:0.59%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.469
ROE:-159.65%
ROA:-22.77%
PB:34.41
PE(LYR):-45.77
PS:58.67

Loading ...

Ascentage Pharma (SEHK:6855): Evaluating Valuation After ASH Meeting Spotlights Pipeline Progress

Simply Wall St.
·
Yesterday

Ascentage Pharma Group International : Btig Initiates Coverage With Buy Rating; Target Price $50

THOMSON REUTERS
·
Nov 10

Ascentage Pharma Group International : Piper Sandler Initiates Coverage With Overweight Rating; Target Price $48

THOMSON REUTERS
·
Nov 05

ASCENTAGE-B (06855) to Showcase Multiple Clinical Advances of Olverembatinib (Nerlynx®), Lisaftoclax (Lisenla®), and APG-5918 at 2025 ASH Annual Meeting, Including One Oral Presentation

Stock News
·
Nov 04

Ascentage Pharma (HKEX: 6855) Announces Multiple Clinical Advancements at the 2025 ASH Annual Meeting

Bulletin Express
·
Nov 04

Ascentage Pharma to Present Phase II Lisaftoclax Trial Results at 2025 ASH Meeting

Reuters
·
Nov 04

Global Major Conference ESMO Enters Countdown, High-Elasticity Hong Kong Stock Connect Innovative Drug ETF (520880) Surges 2%! 3SBIO and ASCENTAGE-B Lead Strong Rally

Deep News
·
Oct 15

Ascentage Pharma Group International to Participate in Citi's 2025 Biopharma Back to School Event

Reuters
·
Aug 29

CICC Maintains Outperform Rating on ASCENTAGE-B (06855), Raises Target Price to HK$105

Stock News
·
Aug 25

Ascentage Pharma Swings to H1 Loss on Weaker Revenue

MT Newswires Live
·
Aug 21

BRIEF-Ascentage Pharma Group International Posts HY Net Loss Was RMB590.8 Million

Reuters
·
Aug 21

Ascentage Pharma Group International H1 Revenue HKD 30.3 Million

THOMSON REUTERS
·
Aug 21

Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates

THOMSON REUTERS
·
Aug 21

ASCENTAGE-B (06855) Reports Interim Results with RMB 234 Million in Revenue; Nerlynx® (Olverembatinib) China Sales Surge 93% Year-over-Year

Stock News
·
Aug 21

Ascentage Pharma Group International - Hy Revenue RMB233.7 Mln

THOMSON REUTERS
·
Aug 21

HK Movers | Biotech Stocks Rally With Brii Biosciences up 14%

Tiger Newspress
·
Aug 18

Ascentage Pharma Wins US and EU Clearance for Lisaftoclax Phase 3 Study

MT Newswires Live
·
Aug 18

Hong Kong Stock Movement | ASCENTAGE-B (06855) Opens Up Over 4% After Lisaftoclax Phase III Clinical Study for Intermediate-to-High Risk MDS Receives FDA and EMA Approval

Stock News
·
Aug 18

BRIEF-Ascentage Pharma Group International FDA And EMA Clear Phase Iii Study Of Lisaftoclax For Hr-Mds

Reuters
·
Aug 18

ASCENTAGE-B (06855): Lestauva® Global Phase III Clinical Trial for First-Line Treatment of Intermediate-High Risk MDS Patients Receives Approval from US FDA and European EMA

Stock News
·
Aug 18